BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu Y, Peng Y, Shen M, Liu L, Lei J, Gao S, Wang Y, Lan A, Li H, Liu S, Raza F. Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients. Journal of Oncology 2022;2022:1-21. [DOI: 10.1155/2022/1525245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu Y, Shen M, Peng Y, Liu L, Tang L, Yang T, Pu D, Tan W, Zhang W, Liu S, Xu Y. Cell Division Cycle-Associated Protein 3 (CDCA3) Is a Potential Biomarker for Clinical Prognosis and Immunotherapy in Pan-Cancer. BioMed Research International 2022;2022:1-28. [DOI: 10.1155/2022/4632453] [Reference Citation Analysis]
2 Xu Y, Jin Y, Gao S, Wang Y, Qu C, Wu Y, Ding N, Dai Y, Jiang L, Liu S, Pan J. Prognostic Signature and Therapeutic Value Based on Membrane Lipid Biosynthesis-Related Genes in Breast Cancer. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/7204415] [Reference Citation Analysis]
3 Xu Y, Shu D, Shen M, Wu Q, Peng Y, Liu L, Tang Z, Gao S, Wang Y, Liu S, Cui D. Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer. Journal of Immunology Research 2022;2022:1-22. [DOI: 10.1155/2022/9412119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]